Javier Naranjo

Javier Naranjo

Auto-generated profile, based on publicly available information

Javier Naranjo

Department of Nephrology, Hospital Universitario Puerta del Mar, Cádiz, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
VMVíctor Martínez
Víctor Martínez
MFMónica Furlano
Mónica Furlano
LSLaia Sans
Laia Sans
LPLissett Pulido
Lissett Pulido
RGRebeca García
Rebeca García
ACAntonio Cabezas
Antonio Cabezas
Background: The clinical manifestations of autosomal dominant polycystic kidney disease (ADPKD) usually appear in adulthood, however pediatric series report a high morbidity. The objective of the study was to analyze the clinical characteristics of ADPKD in young adults. Methods: Family history, hypertension, albuminuria, estimated glomerular filtration rate (eGFR) and imaging tests were examined in 346 young adults (18–30 years old) out of 2521 patients in the Spanish ADPKD registry (REPQRAD). A literature review searched for reports on hypertension in series with more than 50 young (age <30 years) ADPKD patients. Results: The mean age of this young adult cohort was 25.24 (SD 3.72) years. The mean age at diagnosis of hypertension was 21.15 (SD 4.62) years, while in the overall REPQRAD population was aged 37.6 years. The prevalence of hypertension was 28.03% and increased with age (18–24 years, 16.8%; 25–30 years, 36.8%). Although prevalence was lower in women than in men, the age at onset of hypertension (21 years) was similar in both sexes. Mean eGFR was 108 (SD 21) mL/min/1.73 m2, 38.0% had liver cysts and 3.45% of those studied had intracranial aneurysms. In multivariate analyses, hematuria episodes and kidney length were independent predictors of hypertension (area under the curve 0.75). The prevalence of hypertension in 22 pediatric cohorts was 20%–40%, but no literature reports on hypertension in young ADPKD adults were found. Conclusions: Young adults present non-negligible ADPKD-related morbidity. This supports the need for a thorough assessment of young adults at risk of ADPKD that allows early diagnosis and treatment of hypertension.

28 December 2021 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
JNJavier Naranjo
Javier Naranjo
MFMónica Furlano
Mónica Furlano
FTFerran Torres
Ferran Torres
JHJonathan Hernandez
Jonathan Hernandez
MPMarc Pybus
Marc Pybus
RTRoser Torra Torra
Roser Torra Torra
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and shows a wide phenotype. Only patients with rapid progression (RP) are included in clinical trials or are approved to receive disease-modifying drugs. This study aims at comparing different available predictive tools in ADPKD with the Mayo classification (MC) identification of rapid progressors based on high total kidney volume (TKV) according to age. Methods: A total of 164 ADPKD patients were recruited retrospectively from a single centre. The performance of diverse tools to identify RP defined as being in MC categories 1C–1E was assessed. Results: A total of 118 patients were MC 1C–1E. The algorithm developed by the European Renal Association–European Dialysis and Transplant Association Working Group on Inherited Kidney Disorders/European Renal Best Practice had a low sensitivity in identifying MC 1C–1E. The sensitivity and specificity of TKV to predict RP depend on the cut-off used. A kidney length of >16.5 cm before age 45 years has high specificity but low sensitivity. Assessing the MC by ultrasonography had high levels of agreement with magnetic resonance imaging (MRI) data, especially for 1A, 1D and 1E. The estimated glomerular filtration rate (eGFR) decline was very sensitive but had low specificity. In contrast, the Predicting Renal Outcome in Polycystic Kidney Disease (PROPKD) score was very specific but had poor sensitivity. Having hypertension before 35 years of age is a good clinical predictor of MC 1C–1E. Family history can be of help in suggesting RP, but by itself it lacks sufficient sensitivity and specificity. Conclusions: The MC by ultrasonography could be an option in hospitals with limited access to MRI as it performs well generally, and especially at the extremes of the MC, i.e. classes 1A, 1D and 1E. The eGFR decline is sensitive but not very specific when compared with the MC, whereas the PROPKD score is very specific but has low sensitivity. Integrating the different tools currently available to determine RP should facilitate the identification of rapid progressors among patients with ADPKD.

29 September 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
JNJavier Naranjo
Javier Naranjo
FBFrancisco Borrego
Francisco Borrego
JRJosé Luis Rocha
José Luis Rocha
MSMercedes Salgueira
Mercedes Salgueira
MMMaria Adoración Martín-Gomez
Maria Adoración Martín-Gomez
MEMario Espinosa
Mario Espinosa
Background: Tolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the first year of treatment.Methods: A prospective study of an initial cohort of 220 rapidly progressing patients treated with TV for 12 months. The tolerability of TV, the evolution of the estimated glomerular filtration rate (eGFR), analytical parameters, and blood pressure were analyzed.Results: A total of 163 patients (78.2%) received TV for 1 year. The main causes of treatment withdrawal were the aquaretic effects (11%), eGFR deterioration (5%), and hepatic toxicity (2.3%). eGFR decreased significantly after 1 month of treatment without further changes. The decrease in eGFR in the first month was higher in patients with an initially higher eGFR. The eGFR drop during the first year of treatment with TV was lower than that reported by patients in the 2 years prior to TV treatment (–1.7 ± 7.6 vs. –4.4 ± 4.8 mL/min, p = 0.003). Serum sodium and uric acid concentrations increased, and morning urinary osmolality decreased in the first month, with no further changes. Blood pressure decreased significantly without changes in antihypertensive medication.Conclusion: TV treatment is well tolerated by most patients. Liver toxicity is very rare and self-limited. TV reduces eGFR in the first month without showing further changes during the first year of treatment. Patients with a higher starting eGFR will suffer a greater initial drop, with a longer recovery. We suggest using the eGFR observed after a month of treatment as the reference for future comparisons and calculating the rate of eGFR decline in patients undergoing TV treatment.

29 August 2018 in CEN Case Reports
Verified
Journal Article
Closed access
PDF file
JMJavier Naranjo Muñoz
Javier Naranjo Muñoz
CNCarlos Narváez
Carlos Narváez
FVFlorentino Villanego
Florentino Villanego
MMMaría Auxiliadora Mazuecos
María Auxiliadora Mazuecos
MCManuel Ceballos
Manuel Ceballos

5 February 2020 in Transplantation Proceedings
Verified
Journal Article
Closed access
JNJavier Naranjo
Javier Naranjo
FVFlorentino Villanego
Florentino Villanego
JCJuan Manuel Cazorla
Juan Manuel Cazorla
CLCristina León
Cristina León
MLMaría José Ledo
María José Ledo
AMAuxiliadora Mazuecos
Auxiliadora Mazuecos

1 March 2022 in Nefrología
Verified
Journal Article
Open access
FVFlorentino Villanego
Florentino Villanego
LVLuis Alberto Vigara
Luis Alberto Vigara
JTJulia Torrado
Julia Torrado
JNJavier Naranjo
Javier Naranjo
AGAna María García
Ana María García
AMAuxiliadora Mazuecos
Auxiliadora Mazuecos